Capricor Therapeutics, Inc. announced its financial results for Q4 and full year 2025, highlighting a cash balance of approximately $318 million. The company is preparing for a potential launch of Deramiocel for Duchenne muscular dystrophy, with a PDUFA date set for August 22, 2026.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.